Litmus email source
Copy source
<!DOCTYPE html><html lang="en" style="background-color:#ffffff;margin:0;padding:0"><head> <title>Scholar Rock</title> <meta http-equiv="Content-Type" content="text/html; charset=UTF-8"> <meta name="viewport" content="width=device-width"> <!--[if gte mso 9]><xml><o:OfficeDocumentSettings><o:AllowPNG/><o:PixelsPerInch>96</o:PixelsPerInch></o:OfficeDocumentSettings></xml> <![endif]--> <!--[if (gte mso 15)|(IE)]> <style type="text/css"> table{border-collapse:collapse;border-spacing:0;mso-line-height-rule:exactly;mso-margin-bottom-alt:0;mso-margin-top-alt:0;mso-table-lspace:0pt;mso-table-rspace:0pt;} </style> <![endif]--> <!--[if gte mso 9]> <style>li{margin-left:12px !important;mso-special-format:bullet;} </style> <![endif]--> <!--[if gte mso 9]> <style>sup,sub{font-size:100% !important;} </style> <![endif]--> <style>#outlook a{padding:0;}.ReadMsgBody{width:100%;}body,table,td,a{-webkit-text-size-adjust:100%;-ms-text-size-adjust:100%;}table,td{mso-table-lspace:0pt;mso-table-rspace:0pt;}img{-ms-interpolation-mode:bicubic;}body{margin:0;padding:0;}img{border:0;height:auto;line-height:100%;outline:none;text-decoration:none;}table{border-collapse:collapse!important;border-spacing:0!important;}html,body{margin:0 auto!important;padding:0!important;height:100%!important;width:100%!important;}p{margin:0 !important;padding:0!important;}u+.body .listGmail{margin-left:20px!important;} @media (max-width:640px){u+.body .listGmail{margin-left:14px!important;}u+.body .listGmail li{padding-left:6px!important;} }.nolink a{color:inherit!important;text-decoration:none!important;font-size:inherit!important;font-family:inherit!important;font-weight:inherit!important;line-height:inherit!important;} </style> </head> <body width="100%" style="margin:0;color:#000000;font-family:Arial,Helvetica,Verdana,sans-serif;font-size:16px;line-height:22px;mso-line-height-rule:exactly;-webkit-font-smoothing:antialiased;-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;background-color:#ffffff;padding:0;height:100%;width:100%"><center style="width:100%"><div style="display:none;width:0;height:0;max-height:0;line-height:0;mso-hide:all;overflow:hidden;visibility:hidden;padding:0;margin:0;font-size:1px;color:#ffffff; line-height:1px;opacity:0"> Learn how ISEMBYLD can help your patients. ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ </div> <table border="0" cellpadding="0" cellspacing="0" width="100%" style="box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;width:100%" role="none"><tbody><tr><td align="center" style="box-sizing:border-box;font-family:Arial,Helvetica,Verdana,sans-serif;vertical-align:top;background-color:#ffffff" valign="top"> <!--[if mso]> <table border="0" cellpadding="0" cellspacing="0"><tr><td width="600"> <![endif]--><div style="max-width:600px;margin:0 auto;"> <table align="center" width="100%" border="0" cellpadding="0" cellspacing="0" style="box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;" role="none"><tbody><tr><td align="center" style="box-sizing:border-box;background-color:#12A166;padding-left:20px;padding-right:20px;padding-top:6px;padding-bottom:6px"><div style="box-sizing:border-box;text-align:center;display:block;margin:0;margin-bottom:0;mso-line-height-rule:exactly;font-family:Arial,Helvetica, sans-serif;font-size:14px;line-height:18px;font-weight:700;color:#ffffff"> <a href="https://www.isembyldhcp.com/?utm_source=hcp_outlook&utm_medium=email&utm_campaign=hcp_branded&utm_content=isi_0388#isi" target="_blank" style="color:#ffffff;text-decoration:underline">Important Safety Information</a> | <a href="https://scholarrock.com/documents/label/us/ISEMBYLD_PI.pdf?utm_source=hcp_outlook&utm_medium=email&utm_campaign=hcp_branded&utm_content=prescribing_information_header_0388" target="_blank" style="color:#ffffff;text-decoration:underline">Prescribing Information</a></div> </td></tr></tbody></table></div> <!--[if mso]> </td></tr></table> <![endif]--> </td></tr></tbody></table> <table border="0" cellpadding="0" cellspacing="0" width="100%" role="none"><tbody><tr><td align="center"> <table border="0" cellpadding="0" cellspacing="0" width="100%" style="box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;width:100%" role="none"><tbody><tr><td align="center" bgcolor="#ffffff" style="box-sizing:border-box;font-family:Arial,Helvetica,Verdana,sans-serif;vertical-align:top;background-color:#ffffff" valign="top"> <!--[if mso]> <table border="0" cellpadding="0" cellspacing="0"><tr><td width="600"> <![endif]--><div style="max-width:600px;margin:0 auto;"> <table align="center" width="100%" border="0" cellpadding="0" cellspacing="0" style="box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;" role="none"><tbody><tr><td align="center" style="box-sizing:border-box;background-color:#ffffff;padding:20px;padding-left:20px;padding-right:20px;padding-bottom:12px;padding-top:8px"> <table border="0" cellpadding="0" cellspacing="0" width="100%" role="none"><tbody><tr><td align="center" style="border-bottom:1px solid #FF6D6A;padding-bottom:12px"><a href="https://www.isembyldhcp.com/?utm_source=hcp_outlook&utm_medium=email&utm_campaign=hcp_branded&utm_content=isembyld_logo_0388" target="_blank"><img src="https://cdn.scholarrockcommunications.com/campaigns/branded/hcp/2026/outlook-hcp-event-email-cure-sma/logo-isembyld.png" width="250" height="80" border="0" alt="ISEMBYLD brand logo" style="max-width:100%;vertical-align:middle;-ms-interpolation-mode:bicubic"></a> </td></tr><tr><td align="center" valign="top" style="padding-bottom:12px;padding-top:20px;font-family:Arial,Helvetica,sans-serif;font-size:22px;line-height:26px;font-weight:700;color:#00205B">NOW APPROVED </td></tr><tr><td align="center" valign="top" style="padding-bottom:16px;font-family:Arial,Helvetica,sans-serif;font-size:34px;line-height:34px;font-weight:700;color:#00205B">THE FIRST AND ONLY<br><span style="white-space:nowrap;color:#12A166">MUSCLE-TARGETED</span><br>TREATMENT FOR SMA<sup style="line-height:1;font-size:60%">1</sup> </td></tr></tbody></table> <table border="0" cellpadding="0" cellspacing="0" width="100%" role="none"><tbody><tr><td width="20" style="width:20px;"> </td><td align="center" valign="top" style="padding-bottom:16px;font-family:Arial,Helvetica,sans-serif;font-size:14px;line-height:20px;color:#00205B">ISEMBYLD is indicated for the treatment of SMA in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment<sup style="font-size:70%;line-height:1">1</sup> </td><td width="20" style="width:20px;"> </td></tr></tbody></table> <table border="0" cellpadding="0" cellspacing="0" width="100%" role="none"><tbody><tr><td align="left" valign="top" style="padding-bottom:16px;text-align:left;font-family:Arial,Helvetica,sans-serif;font-size:14px;line-height:18px;color:#FF00FB">[Dear/Hello/Hi/Good morning/Good afternoon/Good evening/Greetings] [Dr/Doctor/Miss/Mr/Mrs/Ms/blank] [First Name] [Last Name]<span style="color:#000000">,</span> </td></tr><tr><td align="left" valign="top" style="padding-bottom:12px;text-align:left;font-family:Arial,Helvetica,sans-serif;font-size:14px;line-height:18px;color:#FF00FB">[It’s nice to meet you over email. I want to invite you to register for an upcoming webinar during which you’ll learn about the clinical profile of ISEMBYLD and how to start patients on this new treatment for spinal muscular atrophy (SMA). / I wanted to invite you to register for an upcoming webinar during which you can learn about the mechanism, efficacy, and safety of ISEMBYLD as well as how to get patients started on this new treatment for spinal muscular atrophy (SMA).] </td></tr></tbody></table> </td></tr></tbody></table></div> <!--[if mso]> </td></tr></table> <![endif]--> </td></tr></tbody></table> <table border="0" cellpadding="0" cellspacing="0" width="100%" style="box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;width:100%" role="none"><tbody><tr><td align="center" bgcolor="#ffffff" style="box-sizing:border-box;font-family:Arial,Helvetica,Verdana,sans-serif;vertical-align:top;background-color:#ffffff" valign="top"> <!--[if mso]> <table border="0" cellpadding="0" cellspacing="0"><tr><td width="600"> <![endif]--><div style="max-width:600px;margin:0 auto;"> <table align="center" width="100%" border="0" cellpadding="0" cellspacing="0" style="box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;" role="none"><tbody><tr><td width="20" style="width:20px;background-color:#ffffff"> </td><td align="center" style="box-sizing:border-box;background-color:#00205B;padding:20px;padding-left:32px;padding-right:32px;padding-top:48px;padding-bottom:48px"> <table border="0" cellpadding="0" cellspacing="0" width="100%" role="none"><tbody><tr><td align="center" style="padding-bottom:8px;font-family:Arial,Helvetica,sans-serif;font-size:20px;line-height:24px;font-weight:700;color:#ffffff">A closer look at the first muscle-targeted treatment for SMA </td></tr><tr><td align="center" style="padding-bottom:40px;font-family:Arial,Helvetica,sans-serif;font-size:14px;line-height:16px;color:#ffffff">Hosted by<br><b>Cure SMA</b> </td></tr><tr><td align="center" style="padding-bottom:8px;font-family:Arial,Helvetica,sans-serif;font-size:14px;line-height:16px;color:#ffffff">Presenters<br><p style="font-family:Arial,Helvetica,sans-serif;mso-line-height-rule:exactly;margin:0;margin-bottom:12px;margin-top:12px;text-align:center;font-size:14px;line-height:16px;color:#ffffff"><b>Rebecca McLeod</b><br>Chief Brand Officer and U.S. General Manager, Scholar Rock</p><p style="font-family:Arial,Helvetica,sans-serif; mso-line-height-rule:exactly;margin:0;margin-bottom:12px;text-align:center;font-size:14px;line-height:16px;color:#ffffff"><b>Liz Minko </b><br>VP & Head Trade, Distribution and Patient Services, Scholar Rock</p><p style="font-family:Arial,Helvetica,sans-serif;mso-line-height-rule:exactly;margin:0;margin-bottom:12px;text-align:center;font-size:14px;line-height:16px;color:#ffffff"><b>Anne Stratton, MD, FAAP, FAAPMR</b><br>Associate Professor, Physical Medicine and Rehabilitation, University of Colorado, School of Medicine.</p><p style="font-family:Arial,Helvetica,sans-serif;mso-line-height-rule:exactly;margin:0;margin-bottom:12px;padding-bottom:12px;text-align:center;font-size:14px;line-height:16px;color:#ffffff"><b>Tracy</b><br>Mother and caregiver to a daughter living with SMA</p> </td></tr><tr><td align="center" style="padding-bottom:40px;font-family:Arial,Helvetica,sans-serif;font-size:14px;line-height:16px;color:#ffffff"><b>October 1, 2026 at 11:00 AM CST/12:00 PM EST</b> </td></tr><tr><td align="center"> <table border="0" cellpadding="0" cellspacing="0" width="100%" role="none"><tbody><tr><td align="center"> <table border="0" cellpadding="0" cellspacing="0" role="none"><tbody><tr><td valign="middle" align="center" style="height:32px;width:140px;background-color:#ffffff;text-align:center;color:#00205B"> <a href="https://us02web.zoom.us/webinar/register/WN_AV6HHSQuQC22A2Krmtd2Dg#/registration" target="_blank" style="display:block;width:140px;background-color:#ffffff;padding-left:0;padding-right:0;padding-bottom:8px;padding-top:6px;font-family:Arial,Helvetica,sans-serif;font-size:14px;line-height:18px; font-weight:700;color:#00205B;text-decoration:none">Register Now</a> </td></tr></tbody></table> </td></tr></tbody></table> </td></tr></tbody></table> </td><td width="20" style="width:20px;background-color:#ffffff"> </td></tr></tbody></table></div> <!--[if mso]> </td></tr></table> <![endif]--> </td></tr></tbody></table> </td></tr><tr><td align="center" style="padding-top:8px"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;width:100%" role="none"><tbody><tr><td align="center" bgcolor="#ffffff" style="box-sizing:border-box;font-family:Arial,Helvetica,Verdana,sans-serif;vertical-align:top;background-color:#ffffff" valign="top"> <!--[if mso]> <table border="0" cellpadding="0" cellspacing="0" align="center" style="margin:0 auto;"><tr><td width="600"> <![endif]--> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="max-width:600px;box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;" role="none"><tbody><tr><td align="left" style="box-sizing:border-box;vertical-align:top;background-color:#ffffff;padding:20px" valign="top"><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:8px;font-family:Arial,Helvetica,Verdana,sans-serif;font-weight:bold;font-size:14px; line-height:16px;color:#00205B"> IMPORTANT SAFETY INFORMATION </div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:12px;font-family:Arial,Helvetica,Verdana,sans-serif;font-weight:bold;font-size:14px;line-height:16px;color:#00205B"> WARNINGS AND PRECAUTIONS </div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:8px;font-family:Arial,Helvetica,Verdana,sans-serif;font-weight:bold;font-size:14px;line-height:16px;color: #00205B"> Fractures </div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:12px;font-family:Arial,Helvetica,Verdana,sans-serif;font-weight:normal;font-size:14px;line-height:16px;color:#00205B"> ISEMBYLD may increase the risk of fractures, including serious fractures. Use with caution in patients with a history of low bone density or multiple fractures. In patients who experience fractures, weigh the risks and benefits of continuing ISEMBYLD. </div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:8px;font-family:Arial,Helvetica,Verdana,sans-serif;font-weight:bold;font-size:14px;line-height:16px;color:#00205B"> ADVERSE REACTIONS </div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:12px;font-family:Arial,Helvetica,Verdana,sans-serif;font-weight:normal;font-size:14px;line-height:16px;color:#00205B"> The most common adverse reactions (incidence ≥20% of patients treated with ISEMBYLD and more frequent than placebo) were upper respiratory tract infections, vomiting, cough, other viral infections, headache, gastroenteritis, pharyngitis, and hypersensitivity. </div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:8px;font-family:Arial,Helvetica,Verdana,sans-serif;font-weight:bold;font-size:14px;line-height:16px;color:#00205B"> USE IN SPECIFIC POPULATIONS </div><div style="box-sizing:border-box;text-align:left;display:block; margin:0;margin-bottom:8px;font-family:Arial,Helvetica,Verdana,sans-serif;font-weight:bold;font-size:14px;line-height:16px;color:#00205B"> Pregnancy and Lactation </div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:8px;font-family:Arial,Helvetica,Verdana,sans-serif;font-weight:normal;font-size:14px;line-height:16px;color:#00205B"> Based on animal data, ISEMBYLD may cause fetal harm. There are no adequate data on the developmental risk associated with the use of ISEMBYLD in pregnant women. </div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:12px;font-family:Arial,Helvetica,Verdana,sans-serif;font-weight:normal;font-size:14px;line-height:16px;color:#00205B"> There are no data on the presence of ISEMBYLD in human milk, the effects on the breastfed infant, or the effects of the drug on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ISEMBYLD, and any potential adverse effects on the breastfed infant. </div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:8px;font-family:Arial,Helvetica,Verdana,sans-serif;font-weight:bold;font-size:14px;line-height:16px;color:#00205B"> Females and Males of Reproductive Potential </div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:12px;font-family:Arial,Helvetica,Verdana,sans-serif;font-weight: normal;font-size:14px;line-height:16px;color:#00205B"> Based on animal data, ISEMBYLD may affect male and/or female reproductive function. </div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:12px;font-family:Arial,Helvetica,Verdana,sans-serif;font-weight:bold;font-size:14px;line-height:16px;color:#00205B"> Please see full <a href="https://scholarrock.com/documents/label/us/ISEMBYLD_PI.pdf?utm_source=hcp_outlook&utm_medium=email&utm_campaign=hcp_branded&utm_content=prescribing_information_body_0388" target="_blank" style="text-decoration:underline;color:#00205B">Prescribing Information</a>. </div> </td></tr></tbody></table> <!--[if mso]> </td></tr></table> <![endif]--> </td></tr></tbody></table> </td></tr><tr><td> <table border="0" cellpadding="0" cellspacing="0" width="100%" style="box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;width:100%" role="none"><tbody><tr><td align="center" bgcolor="#ffffff" style="box-sizing:border-box;font-family:Arial,Helvetica,Verdana,sans-serif;vertical-align:top;background-color:#ffffff" valign="top"> <!--[if mso]> <table border="0" cellpadding="0" cellspacing="0"><tr><td width="600"> <![endif]--><div style="max-width:600px;margin:0 auto;"> <table align="center" width="100%" border="0" cellpadding="0" cellspacing="0" style="box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;" role="none"><tbody><tr><td align="center" style="box-sizing:border-box;background-color:#ffffff;padding:20px;padding-left:20px;padding-right:20px;padding-bottom:4px;padding-top:12px"> <table border="0" cellpadding="0" cellspacing="0" width="100%" role="none"><tbody><tr><td align="left" valign="top" style="padding-bottom:20px;text-align:left;font-family:Arial,Helvetica,sans-serif;font-size:14px;line-height:18px;color:#FF00FB">[I hope you’ll be able to join this webinar to learn more about ISEMBYLD. / Please make sure to register for this webinar. / If you're interested in learning more about ISEMBYLD, please let me know and I'll schedule a meeting or call.] </td></tr><tr><td align="left" valign="top" style="padding-bottom:12px;text-align:left;font-family:Arial,Helvetica,sans-serif;font-size:14px;line-height:18px;color:#00205B">Best, </td></tr></tbody></table><div style="box-sizing:border-box;display:block;margin:0;margin-bottom:2px;text-align:left;font-family:Arial,Helvetica,sans-serif;font-size:14px;line-height:18px;font-weight:400;color:#FF00FB"> [Representative first and last name] </div><div style="box-sizing:border-box;display:block;margin:0;margin-bottom:2px;text-align:left;font-family:Arial,Helvetica,sans-serif;font-size:14px;line-height:18px;font-weight:400;color:#FF00FB"> [Representative title] </div><div style="box-sizing:border-box;display:block;margin:0;margin-bottom:2px;text-align:left;font-family:Arial,Helvetica,sans-serif;font-size:14px;line-height:18px;font-weight:400;color:#FF00FB"> [Representative email address] </div><div style="box-sizing:border-box;display:block;margin:0;margin-bottom:2px;text-align:left;font-family:Arial,Helvetica,sans-serif;font-size:14px;line-height:18px;font-weight:400;color:#FF00FB"> [Representative phone number] </div> <table border="0" cellpadding="0" cellspacing="0" width="100%" role="none"><tbody><tr><td align="left" valign="top" style="padding-bottom:32px;padding-top:20px;text-align:left;font-family:Arial,Helvetica,sans-serif;font-size:14px;line-height:18px;color:#00205B">In accordance with applicable state law, pricing information for ISEMBYLD (apitegromab-mstn) is available <a href="https://scholarrock.com/state-regulations-disclosures/?utm_source=hcp_outlook&utm_medium=email&utm_campaign=hcp_branded&utm_content=wac_0388" target="_blank" style="color:#00205B;text-decoration:underline">here</a>. </td></tr><tr><td align="left" style="padding-bottom:8px;text-align:left;font-family:Arial,Helvetica,sans-serif;font-size:10px;line-height:12px;font-weight:700;color:#00205B">Reference: </td></tr><tr><td align="left" style="padding-bottom:4px;text-align:left;font-family:Arial,Helvetica,sans-serif;font-size:10px;line-height:12px;color:#00205B">1. ISEMBYLD. Prescribing Information. Scholar Rock, Inc; 2026. </td></tr></tbody></table> </td></tr></tbody></table></div> <!--[if mso]> </td></tr></table> <![endif]--> </td></tr></tbody></table> </td></tr></tbody></table> <table border="0" cellpadding="0" cellspacing="0" width="100%" style="box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;width:100%;" role="none"><tbody><tr><td align="center" style="box-sizing:border-box;font-family:Arial,Helvetica,Verdana,sans-serif;vertical-align:top;background-color:#ffffff" valign="top"> <!--[if mso]> <table border="0" cellpadding="0" cellspacing="0"><tr><td width="600"> <![endif]--><div style="max-width:600px;margin:0 auto;"> <table align="center" width="100%" border="0" cellpadding="0" cellspacing="0" style="box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;" role="none"><tbody><tr><td align="left" style="box-sizing:border-box;background-color:#00205B;padding-bottom:32px;padding-left:20px;padding-right:20px;padding-top:32px"><div style="box-sizing:border-box;text-align:left;display:block;margin:0 auto;margin-bottom:16px;"> <a href="https://scholarrock.com/?utm_source=hcp_outlook&utm_medium=email&utm_campaign=hcp_branded&utm_content=scholar_rock_logo_0388" target="_blank"><img src="https://cdn.scholarrockcommunications.com/campaigns/branded/hcp/2026/outlook-hcp-event-email-cure-sma/logo-scholar-rock.png" width="120" height="60" border="0" alt="Scholar Rock logo" style="max-width:100%;vertical-align:middle;-ms-interpolation-mode:bicubic;display:inline-block"></a></div><div style="box-sizing:border-box;text-align: left;display:block;margin:0;margin-bottom:20px;font-family:Arial,Helvetica,Verdana,sans-serif;color:#ffffff;font-size:10px;line-height:12px;mso-line-height-rule:exactly;font-weight:normal;"> <a href="https://scholarrock.com/contact-us/?utm_source=hcp_outlook&utm_medium=email&utm_campaign=hcp_branded&utm_content=contact_us_footer_0388" target="_blank" style="color:#ffffff;text-decoration:none;">Contact Us</a> <a href="https://scholarrock.com/privacy-policy/?utm_source=hcp_outlook&utm_medium=email&utm_campaign=hcp_branded&utm_content=privacy_policy_footer_0388" target="_blank" style="color:#ffffff;text-decoration:none;">Privacy Policy</a></div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:12px;font-family:Arial,Helvetica,Verdana,sans-serif;color:#ffffff;font-size:10px;line-height:12px;mso-line-height-rule:exactly;font-weight:normal;"> <span class="nolink">301 Binney Street, 3rd Floor<br> Cambridge, MA 02142</span></div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:12px;font-family:Arial,Helvetica,Verdana,sans-serif;color:#ffffff;font-size:10px;line-height:12px;mso-line-height-rule:exactly;font-weight:normal;"> <span class="nolink">ISEMBYLD is a trademark of Scholar Rock.<br> Scholar Rock © 2026. All rights reserved.<br> US-APIT-0388 09/26</span></div><div style="box-sizing: border-box;text-align:left;display:block;margin:0;margin-bottom:0;font-family:Arial,Helvetica,Verdana,sans-serif;color:#ffffff;font-size:10px;line-height:12px;mso-line-height-rule:exactly;font-weight:normal;"> This advertisement is intended only for healthcare professionals in the United States.<br> Reply with "unsubscribe" to be removed from future ISEMBYLD Marketing communications. </div> </td></tr></tbody></table></div> <!--[if mso]> </td></tr></table> <![endif]--> </td></tr></tbody></table></center> </body></html>